Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinomaOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers examined whether gut microbiome composition affects response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma (HCC). Eight patients with sorafenib-refractory, BCLC Stage C HCC received the anti-PD-1 antibody camrelizumab.
How was it studied?
Fecal samples were collected at baseline and repeatedly during treatment and analyzed by metagenomic sequencing. Patients were classified as responders or non-responders using RECIST 1.1 criteria, and taxa, gene counts, and metabolic pathways were compared between groups.
What did they find?
Responders had higher taxa richness and more gene counts than non-responders. Beta diversity between groups became prominent by Week 6, and in non-responders Proteobacteria increased from Week 3 and became predominant by Week 12. Twenty responder-enriched species were identified, including Akkermansia muciniphila and Ruminococcaceae species, linked to carbohydrate metabolism and methanogenesis pathways.
Why it matters
Early, dynamic shifts in the gut microbiome may help predict which HCC patients will respond to anti-PD-1 immunotherapy. This could support earlier disease monitoring and treatment decisions.